McKinsey has turned the corner on the Asia-centric model of globalization. It’s a “now-or-never” moment for US manufacturing. Here’s where CPA sees eye-to-eye.
From retail investors in China ETFs, to Wall Street’s largest investment firms, China’s new technologies can always count on tens of millions of dollars of inflows from Americans. What do we get in return?
How do we bring back generic drug manufacturing to the United States in order to be less reliant on India, China? A National Academies of Science conference brings in some experts to try and answer that, including the chair of CPA Healthcare Committee.
The trend continues. A Chinese couple indicted over biotech trade secret’s lifted from Ohio research hospital.
Striking all the right chords and buzzwords, China leader Xi Jinping says what the world needs now is love sweet love. Who’s buying?
For Katherine Tai and the Biden administration, environmentalism is going to be the core of trade policy. How does that square with heavy polluters like India and China?
Recent shortages an example of America’s over-bearing dependence on Chinese supply chains. The time is now to take action to reverses this decades-long headwind to U.S. manufacturing and its labor force.
Lawyers from Wiley are telling their clients to prepare for ongoing supply disruptions due to Biden’s China policies.
A Hudson Institute webinar suggests that the U.S. is in a better position to take on China than Europe.
A new bill in the Senate seeks to prevent China solar imports, especially for publicly funded solar installations.
